Global HPV Vaccine Market Analysis and Forecast 2019-2028
$3,150.00 – $5,720.00
Initiatives taken by global health organizations for the HPV vaccines to fuel the market growth
The global HPV vaccine market is expected to observe a robust growth rate of more than 7% during the forecast period. The HPV vaccine is the first vaccine developed specifically targeting the prevention of cervical cancer. Over 200 million doses have been administrated globally. HPV vaccines are used to cure most cervical cancers associated with human papillomavirus (HPV) a sexually transmitted infection. Extensive immunization with the HPV vaccine could reduce the impact of cervical cancer and other cancers caused by HPV globally.
According to the Centre for Disease Control (CDC), the HPV vaccine should be given to children of ages 11 and 12 and can be given as early as 9. The growing prevalence of HPV-associated diseases, initiatives taken by global health organizations like “GAVI”, and the rising number of HPV awareness programs are some of the key factors responsible to fuel the demand for HPV vaccines across the globe. Moreover, high-income countries (HICs) will make up most of this growth, HICs represent approximately 80% of the HPV vaccine market value. However, limited product offerings in various countries are anticipated to act as a barrier to the growth of the global HPV vaccine market.
The 9-Valent Vaccine (Gardasil 9) is dominating the global market
The 9-Valent Vaccine (Gardasil 9) segment is expected to dominate the global HPV vaccine market followed by Quadrivalent Vaccine (Gardasil). Since 2016, only 9-Valent Vaccines is distributing in the US. The reason behind the significant demand for the 9-valent vaccine is this vaccine protects against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58) and is safe and also reduces the further incidence of HPV infections as well as HPV related cancer.
Herd immunity can also be used to protect those who have not received a vaccination. The majority of cervical malignancies can be avoided with an efficient immunization program. Studies reveal that the original quadrivalent HPV vaccine and the 9-valent HPV vaccine are both cost-effective for female patients. Consequently, Bivalent Vaccine (Cervarix) segment is expected to hold a nominal share in the global HPV vaccine market.
Sub-Saharan Africa is a high-potential market for manufacturers across the globe
North America is expected to hold a prominent share of the global HPV vaccine market owing to the rapid adoption of the HPV vaccine across the region. Even in countries like US and Canada where the population has access to ideal sanitation and hygienic conditions cervical cancer is controlled through HPV vaccination. The Asia Pacific is expected to gain significant growth during the forecast period due to the growing incidence of HPV diseases.
Countries like India, and China recorded a sudden increase in the number of cervical cancer cases which directly led to the rising demand for the HPV vaccine in the region. Australia was the first country to introduce the HPV vaccine. In India first HPV vaccine is developed in 2022.
Moreover, there is a potential market for manufacturers in low-income countries. Sub-Saharan Africa has made limited progress in the implementation of HPV vaccines owing to weaken social mobilization over time, inadequate reminder and tracking systems, and vaccine hesitancy. Additionally, public demand for the HPV vaccine may be influenced by the level of knowledge, awareness, and attitude of various stakeholders involved in the HPV vaccination program. According to WHO, In Europe, more than 66,000 women are diagnosed with cervical cancer and more than 30,000 of them die annually from cervical.
In the UK, researchers found that the HPV immunization program has almost eliminated cervical cancer in women born after 1 September 1995 and who were vaccinated at age 12−13. Incidence among these women of late-stage grade 3 CIN that could later develop into cancer has also been significantly reduced.
Explore related report: Global mRNA Technology Market
Market Structure and Competitive Landscape
Some of the prominent players operating in the global HPV vaccine market include Merck & Co., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Johnson & Johnson, AstraZeneca, Walvax Biotechnologies, Innovio Pharmaceuticals, Chengdu Institute of Biological Products Co., Ltd., Sanofi, and Shanghai Bowei among others. Among these, Merck & Co. and GlaxoSmithKline plc are the main makers of the HPV vaccine. These companies use all organic and inorganic growth strategies such as expansion and product launches to increase their offering and their reach across the globe.
- In September 2022, India’s indigenously developed cervical cancer vaccine (qHPV Vaccine) with the partnership between the Serum Institute of India (SII), the Department of Biotechnology (DBT), and the Biotechnology Industry Research Assistance Council (BIRAC).
- In April 2022, Merck & Co. announced to expand its vaccine manufacturing in Virginia to 120,000 square ft. to increase the capacity and supply of HPV vaccine.
Key Market Segmentation
RationalStat has segmented the global HPV vaccine market on the basis of type, disease indication, distribution channel, and region.
- By Type
- 9-Valent Vaccine (Gardasil 9)
- Quadrivalent Vaccine (Gardasil)
- Bivalent Vaccine (Cervarix)
- By Disease Indication
- Cervical Cancer
- Genital Warts
- Oropharyngeal Cancer
- Vulvar Cancer
- Penile Cancer
- Vaginal Cancer
- Anal Cancer
- Others (Head Cancer, Neck Cancer, etc.)
- By Distribution Channel
- Doctor Offices / Hospitals
- School-Based Health Centers
- Government Suppliers
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- US
- Canada
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Western Europe
- Germany
- UK
- France
- Spain
- Italy
- Benelux
- Nordic
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Rest of Eastern Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- ASEAN (Indonesia, Vietnam, Malaysia, etc.)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- South Africa
- Turkey
- Rest of the Middle East & Africa
- North America
Research Methodology
RationalStat has developed a state-of-the-art research methodology to crunch numbers and provide the best possible real-time insights to clients. We combine a varied range of industry experience, data analytics, and experts’ viewpoint to create a research methodology for market sizing and forecasting.
RationalStat combines a mix of secondary sources as well as primary research to assess the HPV vaccine market size and develop a forecast. Key steps involved in accurately deriving the market numbers are:
- Defining the problem by understanding the type of market and data required by the client.
- Data gathering and collection through relevant paid databases, publicly available sources, company reports, annual reports, surveys, and interviews.
- Formulating a hypothesis to create market numbers, forecasts, influencing factors, and their relevance.
- Evaluating and analyzing the data by referring to data sources utilized and leveraged.
- Validating, interpreting, and finalizing the data by combining the details gathered from primary and secondary sources with the help of experienced analysts.
Secondary Sources
- Annual reports, company filings, investor presentations, product catalogs, and company documents
- Industry and market-related documents available in the public domain
- Paid database including Bloomberg, Factiva, S&P Capital IQ, FactSet, Refinitiv Eikon, ICIS, EUWID, and Thomson Reuters, among others
- Whitepapers, research papers, and industry blogs.
Why Buy this Report?
The report is intended for global HPV vaccine manufacturers, vaccine companies and providers, health agencies, healthcare providers, hospitals, government organizations, educational organizations, regulatory agencies, and market research firms, among others. The report provides an in-depth analysis of market size, consumption patterns, ongoing market trends and challenges, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights to clients to find the right answers to their business questions.
Frequently Asked Questions (FAQs)
The Global HPV Vaccine Market is expected to grow at a CAGR of over 7% during the forecast period 2022-2028.
North America is dominating the Global HPV Vaccine Market in 2021.
The Global HPV Vaccine Market is expected to reach US$ 12 billion in 2028.
Initiatives taken by Global Health Organizations for the HPV vaccine are the key drivers of the global HPV Vaccine Market.
Major companies operating in the global HPV vaccine market include Merck & Co., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., etc.
| REGION | Global |
|---|---|
| RELEASE YEAR | 2022 |
| RESEARCH CODE | RST-SAR-082 |
| ADDITIONAL FEATURE | 24×7 Post sales support and 15% free customization |
| User License | Single User/Team License, Corporate License |
Table of Contents
1. Market Introduction
1.1. Scope of Study
1.2. Problem Statement
1.3. Market Segmentation
2. Assumptions and Acronyms
3. Executive Summary
3.1. Global Market in 2022
3.2. Analyst Insights & Recommendations
3.3. Growth Opportunities and Key Strategies
3.4. Supply-side and Demand-side Trends
4. Research Methodology
5. Analysis of COVID-19 Impact and Road Ahead
6. Market Indicators and Background
6.1. Macro-Economic Factors
6.1.1. Global Healthcare Spending
6.1.2. Global Per Capita Spending on Healthcare
6.1.3. Global GDP and Population Overview and Outlook
6.2. Forecasting Factors
Robust assessment of various factors including industrial performance, animal spending, industry players’ expenditures, and economic conditions, among others
6.3. Supply Chain & Value Chain Analysis
6.4. Industry SWOT Analysis
6.5. PESTLE Analysis
6.6. Porter’s Five Forces Analysis
7. Government Laws and Industry Regulations
8. Global and Regional Market Dynamics
8.1. Drivers
8.2. Restraints
8.3. Trends
8.4. Opportunities
9. Global HPV Vaccine Market: Key Investment Analysis
9.1. By Key Industry Players
9.2. By Region
9.3. M&A Activities
Robust assessment of major investments made by various industry players across key regions
10. Parent Market Overview: Healthcare and Pharmaceutical
11. Product Pipeline Analysis
11.1.By Leading Players
11.2.By Stages
11.2.1. Phase I
11.2.2. Phase II
11.2.3. Phase III
11.2.4. Licensed
11.3.By Region
12. Price Analysis
12.1.By Type
12.3.Quadrivalent Vaccine
12.4.Bivalent Vaccine
13. Segmental Analysis
13.1.Global HPV Vaccine Market by Type
13.1.1. Segment Overview
13.1.1.1. 9-Valent Vaccine
13.1.1.2. Quadrivalent Vaccine
13.1.1.3. Bivalent Vaccine
13.2.Global HPV Vaccine Market by Disease Indication
13.2.1. Segment Overview
13.2.1.1. Cervical Cancer
13.2.1.2. Genital Warts
13.2.1.3. Oropharyngeal Cancer
13.2.1.4. Vulvar Cancer
13.2.1.5. Penile Cancer
13.2.1.6. Vaginal Cancer
13.2.1.7. Anal Cancer
13.2.1.8. Others (Head Cancer, Neck Cancer, etc.)
13.3.Global HPV Vaccine Market by Distribution Channel
13.3.1. Segment Overview
13.3.1.1. Doctor Offices / Hospitals
13.3.1.2. School-Based Health Centers
13.3.1.3. Government Suppliers
13.3.1.4. Retail Pharmacies
13.3.1.5. Online Pharmacies
13.4.Global HPV Vaccine Market by Region
13.4.1. North America
13.4.2. Latin America
13.4.3. Western Europe
13.4.4. Eastern Europe
13.4.5. Asia Pacific
13.4.6. Middle East & Africa
14. Regional Analysis
14.1.North America HPV Vaccine Market Analysis and Forecast 2019-2028
14.1.1. Regional Market Overview and Key Takeaways
14.1.2. North America HPV Vaccine Market by Type
14.1.3. North America HPV Vaccine Market by Disease Indication
14.1.4. North America HPV Vaccine Market by Distribution Channel
14.1.5. North America HPV Vaccine Market by Country
14.1.5.1. US
14.2.Latin America HPV Vaccine Market Analysis and Forecast 2019-2028
14.2.1. Regional Market Overview and Key Takeaways
14.2.2. Latin America HPV Vaccine Market by Type
14.2.3. Latin America HPV Vaccine Market by Disease Indication
14.2.4. Latin America HPV Vaccine Market by Distribution Channel
14.2.5. Latin America HPV Vaccine Market by Country
14.2.5.1. Brazil
14.2.5.2. Mexico
14.2.5.3. Rest of Latin America
14.3.Western Europe HPV Vaccine Market Analysis and Forecast 2019-2028
14.3.1. Regional Market Overview and Key Takeaways
14.3.2. Western Europe HPV Vaccine Market by Type
14.3.3. Western Europe HPV Vaccine Market by Disease Indication
14.3.4. Western Europe HPV Vaccine Market by Distribution Channel
14.3.5. Western Europe HPV Vaccine Market by Country
14.3.5.1. Germany
14.3.5.2. UK
14.3.5.3. France
14.3.5.4. Spain
14.3.5.5. Italy
14.3.5.6. Benelux
14.3.5.7. Nordic
14.3.5.8. Rest of Western Europe
14.4.Eastern Europe HPV Vaccine Market Analysis and Forecast 2019-2028
14.4.1. Regional Market Overview and Key Takeaways
14.4.2. Eastern Europe HPV Vaccine Market by Type
14.4.3. Eastern Europe HPV Vaccine Market by Disease Indication
14.4.4. Eastern Europe HPV Vaccine Market by Distribution Channel
14.4.5. Eastern Europe HPV Vaccine Market by Country
14.4.5.1. Russia
14.4.5.2. Poland
14.4.5.3. Rest of Eastern Europe
14.5.Asia Pacific HPV Vaccine Market Analysis and Forecast 2019-2028
14.5.1. Regional Market Overview and Key Takeaways
14.5.2. Asia Pacific HPV Vaccine Market by Type
14.5.3. Asia Pacific HPV Vaccine Market by Disease Indication
14.5.4. Asia Pacific HPV Vaccine Market by Distribution Channel
14.5.5. Asia Pacific HPV Vaccine Market by Country
14.5.5.1. China
14.5.5.2. Japan
14.5.5.3. India
14.5.5.4. South Korea
14.5.5.5. Australia
14.5.5.6. ASEAN
14.5.5.7. Rest of Asia-Pacific
14.6.Middle East & Africa HPV Vaccine Market Analysis and Forecast 2019-2028
14.6.1. Regional Market Overview and Key Takeaways
14.6.2. Middle East & Africa HPV Vaccine Market by Type
14.6.3. Middle East & Africa HPV Vaccine Market by Disease Indication
14.6.4. Middle East & Africa HPV Vaccine Market by Distribution Channel
14.6.5. Middle East & Africa HPV Vaccine Market by Country
14.6.5.1. GCC
14.6.5.2. South Africa
14.6.5.3. Turkey
14.6.5.4. Rest of the Middle East & Africa
15. Competitive Landscape
15.1.Competition Dashboard
15.1.1. Global and Regional Market Share Analysis
15.1.2. Market Structure
15.2.Competitive Benchmarking
15.3.Key Strategy Analysis
15.4.Company Profiles
15.4.1. Merck & Co.
15.4.1.1. Company Overview
15.4.1.2. Source/Service Offerings
15.4.1.3. Key Financials
15.4.1.4. Recent Developments
15.4.2. GlaxoSmithKline plc
15.4.2.1. Company Overview
15.4.2.2. Source/Service Offerings
15.4.2.3. Financials
15.4.2.4. Recent Developments
15.4.3. Serum Institute of India Pvt. Ltd.
15.4.3.1. Company Overview
15.4.3.2. Source/Service Offerings
15.4.3.3. Financials
15.4.3.4. Recent Developments
15.4.4. Johnson & Johnson
15.4.4.1. Company Overview
15.4.4.2. Source/Service Offerings
15.4.4.3. Financials
15.4.4.4. Recent Developments
15.4.5. AstraZeneca
15.4.5.1. Company Overview
15.4.5.2. Source/Service Offerings
15.4.5.3. Financials
15.4.5.4. Recent Developments
15.4.6. Walvax Biotechnologies
15.4.6.1. Company Overview
15.4.6.2. Source/Service Offerings
15.4.6.3. Financials
15.4.6.4. Recent Developments
15.4.7. Innovio Pharmaceuticals
15.4.7.1. Company Overview
15.4.7.2. Source/Service Offerings
15.4.7.3. Financials
15.4.7.4. Recent Developments
15.4.8. Chengdu Institute of Biological Products Co
15.4.8.1. Company Overview
15.4.8.2. Source/Service Offerings
15.4.8.3. Financials
15.4.8.4. Recent Developments
15.4.9. Sanofi
15.4.9.1. Company Overview
15.4.9.2. Source/Service Offerings
15.4.9.3. Financials
15.4.9.4. Recent Developments
15.4.10. Shanghai Bowei
15.4.10.1. Company Overview
15.4.10.2. Source/Service Offerings
15.4.10.3. Financials
15.4.10.4. Recent Developments
16. Disclaimer
List of Figures/Tables
List of Figures
Figure 01: Global HPV Vaccine Market Volume (‘000 units), 2019-2021
Figure 02: Global HPV Vaccine Market Volume (‘000 units) & Y-o-Y Growth (%) Analysis, 2022–2028
Figure 03: HPV Vaccine, Pricing Analysis per unit (US$), in 2022
Figure 04: HPV Vaccine, Pricing Forecast per unit (US$), in 2028
Figure 05: Global HPV Vaccine Market Value Analysis (US$ Mn), 2019-2021
Figure 06: Global HPV Vaccine Market Size (US$ Mn) & Y-o-Y Growth (%) Analysis, 2022–2028
Figure 07: Global HPV Vaccine Market Size and Market Share Analysis (%) by Type, 2022 & 2028
Figure 08: Global HPV Vaccine Market Y-o-Y Analysis (%) by Type, 2022-2028
Figure 09: Global HPV Vaccine Market Size and Market Share Analysis (%) by Disease Indication, 2022 & 2028
Figure 10: Global HPV Vaccine Market Y-o-Y Analysis (%) by Disease Indication, 2022-2028
Figure 11: Global HPV Vaccine Market Size and Market Share Analysis (%) by Distribution Channel, 2022 & 2028
Figure 12: Global HPV Vaccine Market Y-o-Y Analysis (%) by Distribution Channel, 2022-2028
Figure 13: Global HPV Vaccine Market Size and Market Share Analysis (%) by Region, 2022 & 2028
Figure 14: Global HPV Vaccine Market Y-o-Y Growth (%) by Region, 2022–2028
Figure 15: North America HPV Vaccine Market Size and Market Share Analysis (%) by Type, 2022 & 2028
Figure 16: North America HPV Vaccine Market Size and Market Share Analysis (%) by Disease Indication, 2022 & 2028
Figure 17: North America HPV Vaccine Market Size and Market Share Analysis (%) by Distribution Channel, 2022 & 2028
Figure 18: North America HPV Vaccine Market Size and Market Share Analysis (%) by Country, 2022 & 2028
Figure 19: Latin America HPV Vaccine Market Size and Market Share Analysis (%) by Type, 2022 & 2028
Figure 20: Latin America HPV Vaccine Market Size and Market Share Analysis (%) by Disease Indication, 2022 & 2028
Figure 21: Latin America HPV Vaccine Market Size and Market Share Analysis (%) by Distribution Channel, 2022 & 2028
Figure 22: Latin America HPV Vaccine Market Size and Market Share Analysis (%) by Country, 2022 & 2028
Figure 23: Western Europe HPV Vaccine Market Size and Market Share Analysis (%) by Type, 2022 & 2028
Figure 24: Western Europe HPV Vaccine Market Size and Market Share Analysis (%) by Disease Indication, 2022 & 2028
Figure 25: Western Europe HPV Vaccine Market Size and Market Share Analysis (%) by Distribution Channel, 2022 & 2028
Figure 26: Western Europe HPV Vaccine Market Size and Market Share Analysis (%) by Country, 2022 & 2028
Figure 27: Eastern Europe HPV Vaccine Market Size and Market Share Analysis (%) by Type, 2022 & 2028
Figure 28: Eastern Europe HPV Vaccine Market Size and Market Share Analysis (%) by Disease Indication, 2022 & 2028
Figure 29: Eastern Europe HPV Vaccine Market Size and Market Share Analysis (%) by Distribution Channel, 2022 & 2028
Figure 30: Eastern Europe HPV Vaccine Market Size and Market Share Analysis (%) by Country, 2022 & 2028
Figure 31: Asia Pacific HPV Vaccine Market Size and Market Share Analysis (%) by Type, 2022 & 2028
Figure 32: Asia Pacific HPV Vaccine Market Size and Market Share Analysis (%) by Disease Indication, 2022 & 2028
Figure 33: Asia Pacific HPV Vaccine Market Size and Market Share Analysis (%) by Distribution Channel, 2022 & 2028
Figure 34: Asia Pacific HPV Vaccine Market Size and Market Share Analysis (%) by Country, 2022 & 2028
Figure 35: Middle East & Africa HPV Vaccine Market Size and Market Share Analysis (%) by Type, 2022 & 2028
Figure 36: Middle East & Africa HPV Vaccine Market Size and Market Share Analysis (%) by Disease Indication, 2022 & 2028
Figure 37: Middle East & Africa HPV Vaccine Market Size and Market Share Analysis (%) by Distribution Channel, 2022 & 2028
Figure 38: Middle East & Africa HPV Vaccine Market Size and Market Share Analysis (%) by Country, 2022 & 2028
List of Tables
Table 1: Global HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Type
Table 2: Global HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Type
Table 3: Global HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Disease Indication
Table 4: Global HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Disease Indication
Table 5: Global HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Distribution Channel
Table 6: Global HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Distribution Channel
Table 7: Global HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Region
Table 8: Global HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Region
Table 9: North America HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Type
Table 10: North America HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Type
Table 11: North America HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Disease Indication
Table 12: North America HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Disease Indication
Table 13: North America HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Distribution Channel
Table 14: North America HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Distribution Channel
Table 15: North America HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Country
Table 16: North America HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Country
Table 17: Latin America HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Type
Table 18: Latin America HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Type
Table 19: Latin America HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Disease Indication
Table 20: Latin America HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Disease Indication
Table 21: Latin America HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Distribution Channel
Table 22: Latin America HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Distribution Channel
Table 23: Latin America HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Country
Table 24: Latin America HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Country
Table 25: Western Europe HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Type
Table 26: Western Europe HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Type
Table 27: Western Europe HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Disease Indication
Table 28: Western Europe HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Disease Indication
Table 29: Western Europe HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Distribution Channel
Table 30: Western Europe HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028,
Table 31: Western Europe HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Country
Table 32: Western Europe HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Country
Table 33: Eastern Europe HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Type
Table 34: Eastern Europe HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Type
Table 35: Eastern Europe HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Disease Indication
Table 36: Eastern Europe HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Disease Indication
Table 37: Eastern Europe HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Distribution Channel
Table 38: Eastern Europe HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Distribution Channel
Table 39: Eastern Europe HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Country
Table 40: Eastern Europe HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Country
Table 41: Asia Pacific HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Type
Table 42: Asia Pacific HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Type
Table 43: Asia Pacific HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Disease Indication
Table 44: Asia Pacific HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Disease Indication
Table 45: Asia Pacific HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Distribution Channel
Table 46: Asia Pacific HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Distribution Channel
Table 47: Asia Pacific HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Accessories
Table 48: Asia Pacific HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Country
Table 49: Asia Pacific HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Country
Table 50: Middle East & Africa HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Type
Table 51: Middle East & Africa HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Type
Table 52: Middle East & Africa HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Disease Indication
Table 53: Middle East & Africa HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Disease Indication
Table 54: Middle East & Africa HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Distribution Channel
Table 55: Middle East & Africa HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Distribution Channel
Table 56: Middle East & Africa HPV Vaccine Market Value (US$ Mn) Analysis and Forecast 2019-2028, by Country
Table 57: Middle East & Africa HPV Vaccine Market Volume (‘000 units) Analysis and Forecast 2019-2028, by Country
Every Sample Includes
Research Methodology
Complete Table of Contents, List of Charts and Tables
Exclusive Facts & Illustrations
Related products
Healthcare & Pharmaceutical
Global Syndromic Testing Market Analysis and Forecast 2019-2028
Technological advancements in molecular diagnostics fuel the demand for syndromic testing globally
Healthcare & Pharmaceutical
Global Healthcare Information System (HIS) Market Analysis and Forecast 2019-2028
Increasing adoption of IT solutions in healthcare facilities to enhance efficiency is fueling the market growth
Healthcare & Pharmaceutical
Global Molecular Diagnostic Market Analysis and Forecast 2019-2028
Growing demand for personalized medicine coupled with technological advancement is expected to further drive the demand for molecular diagnostics
Healthcare & Pharmaceutical
Global Clinical Diagnostics Market Analysis and Forecast 2019-2028
The increasing healthcare spending and technological advancements are expected to drive the market revenue
Healthcare & Pharmaceutical
Global Core Molecular Laboratory Market Analysis and Forecast 2019-2028
Technological advancements and the adoption of personalized treatment to augment to grow the market revenue
Healthcare & Pharmaceutical
Increasing approvals received for cancer immunotherapies coupled with the rising number of clinical trials drive the NK cell therapeutics market